Consensus and controversy of liquid biopsy using circulating tumour DNA (ctDNA) for molecular residual disease detection in colorectal cancer
The Lancet Regional Health - Western Pacific · 2026-10 · 75 · 102001
DOI: 10.1016/j.lanwpc.2026.102001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Lancet Regional Health - Western Pacific, 2026-10. Verfasst von Alicia Yioli Lefas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London, Surrey, UK. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London, Surrey, UK.
Zitieren
APA
Yioli Lefas, A., & Chau, I. (2026). Consensus and controversy of liquid biopsy using circulating tumour DNA (ctDNA) for molecular residual disease detection in colorectal cancer. The Lancet Regional Health - Western Pacific, 75, 102001. https://doi.org/10.1016/j.lanwpc.2026.102001
Vancouver
Yioli Lefas A, Chau I. Consensus and controversy of liquid biopsy using circulating tumour DNA (ctDNA) for molecular residual disease detection in colorectal cancer. The Lancet Regional Health - Western Pacific. 2026;75:102001. doi:10.1016/j.lanwpc.2026.102001
BibTeX
@article{YioliLefas2026,
author = {Yioli Lefas, Alicia and Chau, Ian},
title = {Consensus and controversy of liquid biopsy using circulating tumour DNA (ctDNA) for molecular residual disease detection in colorectal cancer},
journal = {The Lancet Regional Health - Western Pacific},
year = {2026},
volume = {75},
pages = {102001},
doi = {10.1016/j.lanwpc.2026.102001}
}
EUVIMED